Comparison Between Two Techniques in Treatment of Female Stress Urinary Incontinence

Comparison Between the Effect of Periurethral Injection of Platelet-rich Plasma VS Platelet Rich Fibrin in Treatment of Female Stress Urinary Incontinence

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07366762

Enrollment

Registered

2026-01-26

Start date

2024-07-10

Completion date

2026-01-02

Last updated

2026-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female Stress Urinary Incontinence

Keywords

PRP- i-PRF- SUI

Brief summary

compare the therapeutic effect of periurethral injection of autologous platelet-rich plasma (PRP) and injectable platelet rich fibrin (i-PRF) in treatment of female stress urinary incontinence and comparing the need for re-injection in the two groups.

Interventions

BIOLOGICALPlatelet Rich Plasma

Approximately 5 mL of PRP will be injected at three points (on both sides of the urethra and urethrovaginal space) under local anesthesia. Injections will be performed by gynecologist in the outpatient clinic.

BIOLOGICALPlatelet rich fibrin

Approximately 5 mL of i-PRF will be injected at three points (on both sides of the urethra and urethrovaginal space) under local anesthesia. Injections will be performed by gynecologist in the outpatient clinic

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

30 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Female patients with primary symptoms of SUI confirmed by patient's medical history and clinical examination, including a focused incontinence evaluation * Age range of 30-75 years * Females unfit for surgery * Females with SUI recurrence after previous surgical procedure by suburethal sling * Females refusing surgical interventions

Exclusion criteria

* Residual urine volume exceeding 100 cc after excretion * Evidence of detrusor over-activity on the urodynamic test * Active urinary tract or vaginal infection * Malignancies of the genitourinary system * Patients with genitourinary fistula or urethral diverticulum

Design outcomes

Primary

Measure	Time frame
changes in the severity of SUI measured by Incontinence Impact Questionnaire (IIQ7)	baseline and three and six months follow up

Secondary

Measure	Time frame
changes in the severity of SUI using 10 point visual analogue scale	baseline and three and six months follow up

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026